| Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer H Beltran, D Prandi, JM Mosquera, M Benelli, L Puca, J Cyrta, C Marotz, ... Nature medicine 22 (3), 298-305, 2016 | 1606 | 2016 |
| Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Cancer discovery 7 (5), 462-477, 2017 | 955 | 2017 |
| N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer E Dardenne, H Beltran, M Benelli, K Gayvert, A Berger, L Puca, J Cyrta, ... Cancer cell 30 (4), 563-577, 2016 | 562 | 2016 |
| Patient derived organoids to model rare prostate cancer phenotypes L Puca, R Bareja, D Prandi, R Shaw, M Benelli, WR Karthaus, J Hess, ... Nature communications 9 (1), 2404, 2018 | 338 | 2018 |
| A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers H Beltran, C Oromendia, DC Danila, B Montgomery, C Hoimes, ... Clinical Cancer Research 25 (1), 43-51, 2019 | 251 | 2019 |
| ONECUT2 is a driver of neuroendocrine prostate cancer H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ... Nature communications 10 (1), 278, 2019 | 226 | 2019 |
| Emerging variants of castration-resistant prostate cancer PJ Vlachostergios, L Puca, H Beltran Current oncology reports 19, 1-10, 2017 | 215 | 2017 |
| Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer L Puca, K Gavyert, V Sailer, V Conteduca, E Dardenne, M Sigouros, ... Science translational medicine 11 (484), eaav0891, 2019 | 171 | 2019 |
| N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer A Berger, NJ Brady, R Bareja, B Robinson, V Conteduca, MA Augello, ... The Journal of clinical investigation 129 (9), 3924-3940, 2019 | 170 | 2019 |
| Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets F Tang, D Xu, S Wang, CK Wong, A Martinez-Fundichely, CJ Lee, ... Science 376 (6596), eabe1505, 2022 | 153 | 2022 |
| Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies L Puca, PJ Vlachostergios, H Beltran Cold Spring Harbor perspectives in medicine 9 (2), a030593, 2019 | 119 | 2019 |
| Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity J Cyrta, A Augspach, MR De Filippo, D Prandi, P Thienger, M Benelli, ... Nature communications 11 (1), 5549, 2020 | 108 | 2020 |
| SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ... Molecular cancer therapeutics 19 (5), 1157-1164, 2020 | 70 | 2020 |
| α-arrestin 1 (ARRDC1) and β-arrestins cooperate to mediate Notch degradation in mammals L Puca, P Chastagner, V Meas-Yedid, A Israël, C Brou Journal of Cell Science 126 (19), 4457-4468, 2013 | 66 | 2013 |
| α-Arrestins–new players in Notch and GPCR signaling pathways in mammals L Puca, C Brou Journal of Cell Science 127 (7), 1359-1367, 2014 | 52 | 2014 |
| Integrative molecular analysis of patients with advanced and metastatic cancer V Sailer, KW Eng, T Zhang, R Bareja, DJ Pisapia, A Sigaras, B Bhinder, ... JCO precision oncology 3, 1-12, 2019 | 44 | 2019 |
| Extracellular matrix in synthetic hydrogel‐based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors MJ Mosquera, S Kim, R Bareja, Z Fang, S Cai, H Pan, M Asad, ML Martin, ... Advanced Materials 34 (2), 2100096, 2022 | 43 | 2022 |
| Akt regulates drug-induced cell death through Bcl-w downregulation M Garofalo, C Quintavalle, C Zanca, A De Rienzo, G Romano, M Acunzo, ... PloS one 3 (12), e4070, 2008 | 33 | 2008 |
| Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer M Che, A Chaturvedi, SA Munro, SP Pitzen, A Ling, W Zhang, J Mentzer, ... Nature communications 12 (1), 6377, 2021 | 31 | 2021 |
| An emerging role for cytopathology in precision oncology C Pauli, L Puca, JM Mosquera, BD Robinson, H Beltran, MA Rubin, ... Cancer cytopathology 124 (3), 167-173, 2016 | 31 | 2016 |
